Adeno-associated virus vector-mediated production of hepatocyte growth factor attenuates liver fibrosis in mice

Hepatology International

Volumn 2, Issue 1, 2008, Pages 80-88

  Suzumura, Kazuhiro ^a   Hirano, Tadamichi ^a   Son, Gakuhei ^a   Iimuro, Yuji ^a   Mizukami, Hiroaki ^b   Ozawa, Keiya ^b   Fujimoto, Jiro ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

AAV; BDL; CCl4; HGF; Liver fibrosis

Indexed keywords

BIOLOGICAL MARKER; CARBON TETRACHLORIDE; COLLAGENASE; COMPLEMENTARY DNA; PARVOVIRUS VECTOR; RNA; SCATTER FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SERUM; STAINING; STELLATE CELL; VIRAL GENE THERAPY;

EID: 69749103204     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-007-9042-1     Document Type: Article

References (42)

1. Pinzani M, Romanelli RG, Magli S. Progression of fibrosis in chronic liver diseases: Time to tally the score. J Hepatol 2001;34:764-7.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
3. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al., For the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
6. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al., For the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
7. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450-9.
8. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
9. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-6.
10. Boros P, Miller CM. Hepatocyte growth factor: A multi functional cytokine. Lancet 1995;345:293-5.
11. Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C, et al. HGF receptor associates with anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996;15:6205-12.
12. Matsuda Y, Matsumoto K, Yamada A, Ichida T, Asakura H, Komoriya Y, et al. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology 1997;26:81-9.
13. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA 1994;91:4357-61.
14. Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, et al. Importance of the liver in plasma clearance of hepatocyte growth factors in rats. Am J Physiol 1992;263:G642-9.
15. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-30.
16. Hirano T, Fujimoto J, Ueki T, Yamamoto H, Iwasaki T, Morisita R, et al. Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Ther 1998;5:459-64.
17. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997;16:270-6.
18. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winther B, et al. The kinetics of rAAV integration in the liver. Nat Genet 1998;19:13-5.
19. Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S. Organization of the human hepatocyte growth factor-encoding gene. Gene 1991;102:213-9.
20. Chiorini JA, Kim F, Yang L, Kotin RM. Cloning and characterization of adeno-associated virus type 5. J Virol 1999;73:1309-19.
21. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998;5:938-45.
22. Paquet KJ, Kamphausen U. The carbon-tetrachloride-hepatotoxicity as a model of liver damage. First report: Long-time biochemical changes. Acta Hepatogastroenterol (Stuttg) 1975;22:84-8.
23. Ezure T, Sakamoto T, Tsuji H, Lunz JG 3rd, Murase N, Fung JJ, et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 2000;156:1627-39.
24. Wasylyk C, Gutman A, Nicholson R, Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991;10:1127-34.
25. Westermarck J, Seth A, Kahari VM. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997;14:2651-60.
26. Ozaki I, Zhao G, Mizuta T, Ogawa Y, Hara T, Kajihara S, et al. Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J Hepatol 2002;36:169-78.
27. Wu J, Norton PA. Animal models of liver fibrosis. Scand J Gastroenterol 1996;31:1137-43.
28. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994;41:343-8.
29. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
30. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
31. Ozawa S, Uchiyama K, Nakamori M, Ueda K, Iwahashi M, Ueno H, et al. Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy. Surgery 2006;139:563-73.
32. Lin Y, Xie WF, Chen YX, Zhang X, Zeng X, Qiang H, et al. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int 2005;25:796-807.
33. Oe H, Kaido T, Furuyama H, Mori A, Imamura M. Simultaneous transfer of vascular endothelial growth factor and hepatocyte growth factor genes effectively promotes liver regeneration after hepatectomy in cirrhotic rats. Hepatogastroenterology 2004;51:1641-7.
34. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993;4:403-9.
35. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286:2244-5.
36. Nathwani AC, Davidoff AM, Hanawa H, Hu Y, Hoffer FA, Nikanorov A, et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002;100:1662-9.
37. Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, Spence Y, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005;11(6):875-88.
38. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-61.
39. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-72.
40. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701-6.
41. Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1992;89:373-7.
42. Santoni-Rugiu E, Preisegger KH, Kiss A, Audolfsson T, Shiota G, Schmidt EV, et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci USA 1996;93:9577-82.